MCU and metabolic dysfunction-associated steatohepatitis: Using a CDAHFD-fed mouse model to rapidly develop MASH with progressive liver fibrosis [29, 30], we have shown that hepatic MCU knockdown robustly mitigated multiple aspects of the disease, including steatosis, inflammation, and fibrosis, as well as improved hepatic oxidative stress and mitochondrial dysfunction.